Quick Answer
Design Therapeutics, Inc. reported Stockholders Equity of $212.50 million for fiscal year 2025.
Design Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $212.50M | -12.2% |
| 2024 | $242.10M | -12.8% |
| 2023 | $277.69M | -15.2% |
| 2022 | $327.31M | -14.3% |
| 2021 | $382.13M | +3477.2% |
| 2020 | -$11.31M | -210.7% |
| 2019 | -$3.64M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $199.72M | -20.9% | -6.3% |
| June 30, 2025 | $213.04M | -18.5% | -6.5% |
| March 31, 2025 | $227.92M | -15.4% | -5.9% |
| December 31, 2024 | $242.10M | -12.8% | -4.1% |
| September 30, 2024 | $252.45M | -11.4% | -3.4% |
| June 30, 2024 | $261.24M | -12.0% | -3.1% |
| March 31, 2024 | $269.56M | -13.8% | -2.9% |
| December 31, 2023 | $277.69M | -15.2% | -2.6% |
- Design Therapeutics, Inc. showed a decrease of -12.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Design Therapeutics, Inc.’s stockholders equity has grown by 5934.8% (from -$3.64 million to $212.50 million).
- The most recent figure is from Design Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: